Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   3:59:59 PM EDT
516.62
-0.55 (-0.11%)
4:07:29 PM EDT: $516.01 -0.61 (-0.12%)
Products

Sanofi: FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis

Published: 09/14/2020 05:08 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis.
Designation Based on Positive Results From Part a of Pivotal Phase 3 Trial.
Dupixent is First and Only Biologic to Show Positive and Clinically-meaningful Phase 3 Results in Patients 12 Years and Older With Eosinophilic Esophagitis (eoe).